Your browser doesn't support javascript.
loading
A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3.
Zwolak, Adam; Chan, Szeman Ruby; Harvilla, Paul; Mahady, Sally; Armstrong, Anthony A; Luistro, Leopoldo; Tamot, Ninkka; Yamada, Douglas; Derebe, Mehabaw; Pomerantz, Steven; Chiu, Mark; Ganesan, Rajkumar; Chowdhury, Partha.
Afiliación
  • Zwolak A; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA. azwolak1@its.jnj.com.
  • Chan SR; Oncology Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Harvilla P; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Mahady S; Oncology Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Armstrong AA; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Luistro L; Oncology Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Tamot N; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Yamada D; Oncology Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Derebe M; Merck Research Laboratories, Discovery Biologics, Protein Sciences, South San Francisco, CA, USA.
  • Pomerantz S; Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA.
  • Chiu M; Tavotek Biotherapeutics, Spring House, PA, USA.
  • Ganesan R; Immunotherapeutics, Amgen, South San Francisco, CA, USA.
  • Chowdhury P; Cell Engineering and Early Development, Janssen Research & Development, Spring House, PA, USA.
Sci Rep ; 12(1): 20538, 2022 11 29.
Article en En | MEDLINE | ID: mdl-36446890
TL1A (TNFSF15) is a TNF superfamily ligand which can bind the TNFRSF member death receptor 3 (DR3) on T cells and the soluble decoy receptor DcR3. Engagement of DR3 on CD4+ or CD8+ effector T cells by TL1A induces downstream signaling, leading to proliferation and an increase in secretion of inflammatory cytokines. We designed a stable recombinant TL1A molecule that (1) displays high monodispersity and stability, (2) displays the ability to activate T cells in vitro and in vivo, and (3) lacks binding to DcR3 while retaining functional activity via DR3. Together these results suggest the TL1A ligand can be amenable to therapeutic development on its own or paired with a tumor-targeting moiety.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T / Miembro 15 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T / Miembro 15 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos